January 1982

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia

Author Affiliations

From the Long Island Jewish-Hillside Medical Center, Glen Oaks, NY (Drs Kane, Nayak, and Ramos-Lorenzi), the Psychiatric Institute, New York (Dr Quitkin), and Mount Sinai School of Medicine, New York (Dr Rifkin).

Arch Gen Psychiatry. 1982;39(1):70-73. doi:10.1001/archpsyc.1982.04290010048009

• Twenty-eight patients who had recently recovered from an acute-onset, first-episode schizophrenic illness were randomly given fluphenazine hydrochloride or decanoate or placebo for a one-year period in a double-blind study. Seven of 17 patients (41%) receiving placebo experienced a psychotic relapse, whereas none of 11 drug-treated patients experienced a relapse. Eighteen (69%) of the 26 patients available for follow-up (mean interval, 3.5 years) experienced a second psychotic relapse either during the study or afterward, and 50% (14/28) of the original sample experienced a third episode.